Intro -- Title Page -- Preface -- Contents -- Clinical Trials for Disease-Modifying Therapies in Alzheimer''s Disease: A Primer, Lessons Learned, and a Blueprint for the Future -- Targeting Alzheimer''s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment -- Lost in Translation? Finding Our Way To Effective Alzheimer''s Disease Therapies -- The End of the Beginning of the Alzheimer''s Disease Nightmare: A Devil''s Advocate''s View -- Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology -- Multifactorial Hypothesis and Multi-Targets for Alzheimer''s Disease -- Dementia Research: Populations, Progress, Problems, and Predictions -- Three Decades of Dementia Research: Insights from One Small Community of Indomitable Rotterdammers -- Religious Orders Study and Rush Memory and Aging Project -- Prevention Matters: Time for Global Action and Effective Implementation -- Multimodal Neuroimaging in Alzheimer''s Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle -- Preclinical Alzheimer''s Disease: Implications for Refinement of the Concept -- Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review -- The Relationship between Obstructive Sleep Apnea and Alzheimer''s Disease -- From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer''s Disease -- Cerebrospinal Fluid Biomarkers in Alzheimer''s Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment -- A Blood Test for Alzheimer''s Disease: Progress, Challenges, and Recommendations -- Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer''s Disease -- Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer''s Disease -- Toward a New Concept of Alzheimer''s Disease Models: A Perspective from Neuroinflammation -- Role of Neuroinflammation in the Trajectory of Alzheimer''s Disease and in vivo Quantification Using PET -- Microglial Activation During Pathogenesis of Tauopathy in rTg4510 Mice: Implications for the Early Diagnosis of Tauopathy -- Conquering Alzheimer''s Disease by Self Treatment -- Past to Future: What Animal Models Have Taught Us About Alzheimer''s Disease -- Iron and Alzheimer''s Disease: An Update on Emerging Mechanisms -- Brain Aging and Late-Onset Alzheimer''s Disease: A Matter of Increased Amyloid or Reduced Energy? -- Metabolic Dysfunction in Alzheimer''s Disease: From Basic Neurobiology to Clinical Approaches -- Targeting Insulin for Alzheimer''s Disease: Mechanisms, Status and Potential Directions -- Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer''s Disease -- Perspectives on Oxidative Stress in Alzheimer''s Disease and Predictions of Future Research Emphases -- Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase -- Findings from the Swedish Study on Familial Alzheimer''s Disease Including the APP Swedish Double Mutation -- Untold New Beginnings: Adult Hippocampal Neurogenesis and Alzheimer''s Disease -- Our Tau Tales from Normal to Pathological Behavior -- Amyloid-Beta and Tau in Alzheimer''s Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies -- New Beginnings in Alzheimer''s Disease: The Most Prevalent Tauopathy -- Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation -- The Conundrum of GSK3 Inhibitors: Is it the Dawn of a New Beginning? -- Tau Immunotherapies for Alzheimer''s Disease and Related Tauopathies: Progress and Potential Pitfalls -- The Amyloid-Beta Oligomer Hypothesis: Beginning of the Third Decade -- Role of Amyloid-Beta and Tau Proteins in Alzheimer''s Disease: Confuting the Amyloid Cascade -- Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer''s Disease -- Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration -- Amyloid-Beta/Drug Interactions from Computer Simulations and Cell-Based Assays -- .